5 Key Takeaways
-
1
Suprachoroidal injections offer targeted drug delivery to chorioretinal tissues, minimizing exposure to unaffected ocular structures.
-
2
The FDA approved Xipere for suprachoroidal use in treating uveitic macular edema, marking a significant advancement in ocular therapeutics.
-
3
Suprachoroidal drug delivery achieves durable drug levels in the retina while limiting adverse effects associated with anterior-segment exposure.
-
4
Innovative delivery systems, such as catheter-based and microneedle-based platforms, enhance patient convenience and expand access to treatments.
-
5
Recent clinical trials demonstrate the effectiveness of new technologies, including the Everads Injector and Orbit Subretinal Delivery System, for ocular therapies.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.